Stock Traders Buy High Volume of Put Options on Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics, Inc. (NASDAQ:SLNO) saw some unusual options trading on Monday. Investors acquired 5,314 put options on the company. This is an increase of 109% compared to the typical daily volume of 2,540 put options.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Analysts still show support: SLNO retains a consensus rating of “Moderate Buy,” which could limit downside if fundamentals or clinical updates improve. Analyst Consensus Article
• Neutral Sentiment: Market visibility: coverage notes that SLNO has gained attention in the Nasdaq composite today — this can amplify moves (both up and down) as momentum traders respond. Market Attention Article
• Negative Sentiment: Class‑action litigation: a securities class action has been filed alleging Soleno concealed drug safety risks and that the company’s November 2025 DCCR/VYKAT™ XR disclosures harmed investors. That complaint (and related press) is the core negative catalyst investors cite. Hagens Berman Article
• Negative Sentiment: Multiple law firms soliciting plaintiffs: numerous firms (Rosen, Glancy Prongay Wolke & Rotter, Faruqi & Faruqi, Levi & Korsinsky, Robbins Geller, Kaplan Fox, Schall, DJS, etc.) have issued notices reminding investors of a May 5, 2026 lead‑plaintiff deadline and encouraging filings — increasing media attention and legal risk premium on the stock. Rosen Notice
• Negative Sentiment: Put buying surge: unusually large options activity — ~5,314 put contracts traded (≈109% above typical put volume) — signals increased bearish positioning and hedging demand, which can amplify downward pressure on the share price. (Intraday options flow reported by market data.)

Institutional Trading of Soleno Therapeutics

Several large investors have recently modified their holdings of the business. Wellington Management Group LLP grew its position in shares of Soleno Therapeutics by 272.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after buying an additional 1,691,057 shares during the last quarter. Braidwell LP bought a new position in Soleno Therapeutics in the 3rd quarter worth $86,662,000. Janus Henderson Group PLC raised its holdings in Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock worth $332,302,000 after purchasing an additional 1,122,015 shares in the last quarter. Invesco Ltd. lifted its position in shares of Soleno Therapeutics by 132.3% in the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after purchasing an additional 854,551 shares during the period. Finally, Commodore Capital LP lifted its position in shares of Soleno Therapeutics by 121.3% in the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock worth $91,260,000 after purchasing an additional 740,000 shares during the period. 97.42% of the stock is owned by institutional investors.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock opened at $33.39 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. Soleno Therapeutics has a one year low of $32.63 and a one year high of $90.32. The business’s 50 day simple moving average is $40.50 and its two-hundred day simple moving average is $50.69. The stock has a market capitalization of $1.72 billion, a P/E ratio of 145.18 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. Analysts forecast that Soleno Therapeutics will post -3.72 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on SLNO shares. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a research note on Monday, January 12th. Wells Fargo & Company decreased their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. TD Cowen cut their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Finally, Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.85.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.